TABLE 3.

Serum HAI antibody seroconversion rates to the A/H1N1, A/H3N2, and B influenza virus strains

Serostatus,b strain, and treatment	nc	Serum HAI seroconversiona
		No. (%)	Significanced
All subjects
A/H1N1
CAIV-T 107	40	8 (20.0)	N/A
CAIV-T <105	40	2 (5.0)	0.087
TIV	42	15 (35.7)	0.143
Placebo	40	3 (7.5)	0.193
A/H3N2
CAIV-T 107	40	28 (70.0)	N/A
CAIV-T <105	40	3 (7.5)	<0.001
TIV	42	10 (23.8)	<0.001
Placebo	40	4 (10.0)	<0.001
B
CAIV-T 107	40	21 (52.5)	N/A
CAIV-T <105	39	7 (17.9)	0.002
TIV	42	12 (28.6)	0.042
Placebo	39	7 (17.9)	0.002
Seronegative subjects
A/H1N1
CAIV-T 107	33	7 (21.1)	N/A
CAIV-T <105	29	1 (3.4)	0.057
TIV	30	5 (16.7)	0.754
Placebo	30	3 (10.0)	0.308
A/H3N2
CAIV-T 107	33	27 (81.8)	N/A
CAIV-T <105	34	3 (8.8)	<0.001
TIV	35	7 (20.0)	<0.001
Placebo	34	4 (11.8)	<0.001
B
CAIV-T 107	27	19 (70.4)	N/A
CAIV-T <105	21	5 (23.8)	0.003
TIV	26	5 (19.2)	<0.001
Placebo	24	6 (25.0)	0.002

^aSeroconversion to a particular virus strain was defined as a ≥1:4-fold rise from baseline in the titer of HAI antibody to that strain.

^bA subject was seronegative to a particular strain if his or her prevaccination HAI titer to that strain was ≤1:4.

^cNumber of subjects with complete data.

^dP values based on comparison with the CAIV-T 10⁷ treatment group were calculated by a two-sided Fisher exact test.